CD4 and neoplasm: The agonist anti-TNFRSF4 antibody is used to inhibit metastasis of metastatic cutaneous squamous cell carcinoma (mSCC) by significantly inhibiting Tregs and by improving the infiltration of tumor-associated CD4+ T cells (131).